Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000168056 | SCV000218709 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2022-06-04 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PMS2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 188162). This variant has not been reported in the literature in individuals affected with PMS2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 568 of the PMS2 protein (p.Pro568Ser). |
| Ambry Genetics | RCV002408726 | SCV002715776 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-11 | criteria provided, single submitter | clinical testing | The p.P568S variant (also known as c.1702C>T), located in coding exon 11 of the PMS2 gene, results from a C to T substitution at nucleotide position 1702. The proline at codon 568 is replaced by serine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |